Adaptimmune Therapeutics plc [NASDAQ: ADAP] loss -7.80% or -0.35 points to close at $4.14 with a heavy trading volume of 2659789 shares. The company report on May 20, 2021 that Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial.
– Data will support BLA filing for afamitresgene autoleucel next year -.
– Responses observed across a broad range of antigen expression -.
It opened the trading session at $4.48, the shares rose to $4.5289 and dropped to $3.80, the range by which the price of stock traded the whole day. The daily chart for ADAP points out that the company has recorded 3.50% gains over the past six months. However, it is still -9.23% lower than its most recent low trading price.
If we look at the average trading volume of 849.70K shares, ADAP reached to a volume of 2659789 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adaptimmune Therapeutics plc [ADAP]:
Barclays have made an estimate for Adaptimmune Therapeutics plc shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on May 28, 2021. While these analysts kept the previous recommendation, Mizuho raised their target price to Neutral. The new note on the price target was released on April 22, 2020, representing the official price target for Adaptimmune Therapeutics plc stock.
The Average True Range (ATR) for Adaptimmune Therapeutics plc is set at 0.30, with the Price to Sales ratio for ADAP stock in the period of the last 12 months amounting to 186.40. The Price to Book ratio for the last quarter was 2.08, with the Price to Cash per share for the same quarter was set at 1.96.
Trading performance analysis for ADAP stock
Adaptimmune Therapeutics plc [ADAP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.73. With this latest performance, ADAP shares dropped by -14.11% in over the last four-week period, additionally plugging by 3.50% over the last 6 months – not to mention a drop of -60.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADAP stock in for the last two-week period is set at 30.75, with the RSI for the last a single of trading hit 23.71, and the three-weeks RSI is set at 35.49 for Adaptimmune Therapeutics plc [ADAP]. The present Moving Average for the last 50 days of trading for this stock 4.98, while it was recorded at 4.47 for the last single week of trading, and 5.77 for the last 200 days.
Adaptimmune Therapeutics plc [ADAP]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Adaptimmune Therapeutics plc [ADAP] shares currently have an operating margin of -3839.26. Adaptimmune Therapeutics plc’s Net Margin is presently recorded at -3286.81.
Return on Total Capital for ADAP is now -59.58, given the latest momentum, and Return on Invested Capital for the company is -51.54. Return on Equity for this stock declined to -56.41, with Return on Assets sitting at -41.44. When it comes to the capital structure of this company, Adaptimmune Therapeutics plc [ADAP] has a Total Debt to Total Equity ratio set at 6.95. Additionally, ADAP Total Debt to Total Capital is recorded at 6.50, with Total Debt to Total Assets ending up at 5.26. Long-Term Debt to Equity for the company is recorded at 6.14, with the Long-Term Debt to Total Capital now at 5.74.
Reflecting on the efficiency of the workforce at the company, Adaptimmune Therapeutics plc [ADAP] managed to generate an average of -$283,775 per employee. Receivables Turnover for the company is 0.19 with a Total Asset Turnover recorded at a value of 0.01.Adaptimmune Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.50 and a Current Ratio set at 11.50.
Adaptimmune Therapeutics plc [ADAP]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adaptimmune Therapeutics plc posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADAP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptimmune Therapeutics plc go to 1.00%.
An analysis of insider ownership at Adaptimmune Therapeutics plc [ADAP]
There are presently around $487 million, or 77.30% of ADAP stock, in the hands of institutional investors. The top three institutional holders of ADAP stocks are: MATRIX CAPITAL MANAGEMENT COMPANY, LP with ownership of 38,974,185, which is approximately 0% of the company’s market cap and around 1.30% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 17,082,611 shares of the stock with an approximate value of $70.72 million in ADAP stocks shares; and BAILLIE GIFFORD & CO, currently with $47.48 million in ADAP stock with ownership of nearly 10.714% of the company’s market capitalization.
Positions in Adaptimmune Therapeutics plc stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 44 institutional holders increased their position in Adaptimmune Therapeutics plc [NASDAQ:ADAP] by around 6,122,024 shares. Additionally, 37 investors decreased positions by around 6,668,491 shares, while 20 investors held positions by with 104,754,765 shares. The mentioned changes placed institutional holdings at 117,545,280 shares, according to the latest SEC report filing. ADAP stock had 17 new institutional investments in for a total of 2,042,132 shares, while 16 institutional investors sold positions of 4,185,247 shares during the same period.